Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting [Yahoo! Finance]
Verrica Pharmaceuticals Inc. (VRCA)
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate – – Coupled with VP-315's previously reported safety profile, these results highlight VP-315's potential as a first-in-class, non-surgical immunotherapeutic option for patients with basal cell carcinoma – WEST CHESTER, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the presentation of new data from its Phase 2 study evaluating VP-315 (ruxotemitide), a novel oncolytic peptide immunotherapy, at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting which took place November 5–9, 2025, in N
Show less
Read more
Impact Snapshot
Event Time:
VRCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRCA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRCA alerts
High impacting Verrica Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VRCA
News
- Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash RunwayGlobeNewswire
- Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Verrica Pharmaceuticals Non-GAAP EPS of $0.13, revenue of $14.3M [Seeking Alpha]Seeking Alpha
- Verrica Pharmaceuticals Reports Third Quarter 2025 Financial ResultsGlobeNewswire
- Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual MeetingGlobeNewswire
VRCA
Earnings
- 11/14/25 - Beat
VRCA
Sec Filings
- 12/3/25 - Form SCHEDULE
- 11/28/25 - Form SCHEDULE
- 11/25/25 - Form 4
- VRCA's page on the SEC website